Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Eyes Opportunity To Transform Asthma Rescue Treatment

Executive Summary

The company plans to file PT027, a new fixed-dose combination of albuterol and budesonide, in 2022 following two positive Phase III trials showing a benefit on lung function.

You may also be interested in...



AstraZeneca Rejigs Respiratory Franchise With Fresh Covis Deal

Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.

Amgen And AstraZeneca Tout Fresh Tezepelumab Data

Recently-submitted tezepelumab reduced the annualized asthma exacerbation rate by 86% in a subgroup of patients with severe, uncontrolled asthma and nasal polyps, according to data presented at the European Respiratory Society congress.

Lots To Celebrate Among 2021 Drug Launches, But Underlying Trends Underwhelm

The number of new drugs that launched in 2021 was on par with recent high trends, but launch trajectories generally underwhelmed commercially – except for COVID-19 vaccines.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel